Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer.
Proteolytic destruction of basement membrane and tumor surrounding is a prerequisite of invasion and metastasis. In 587 frozen samples of malignant and nonmalignant tissue of breast, uterus, vulva, and ovary, levels of urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) were examined with enzyme-linked immunosorbent assay (ELISA) and cathepsin D (cath D) with radioimmunoassay. UPA, PAI-1 and cath D were raised in malignant tissue with significantly higher levels in breast cancer (uPA, PAI-1) and ovarian cancer (cath D). TPA levels were lower in malignant tissue. In 393 primary breast cancer samples, uPA, PAI-1, and cath D were not related to other prognostic factors, whereas tPA levels were significantly raised in prognostic more favorable carcinomas. Over a follow-up period up to 46 months (median 30 months) the log-rank test showed in the whole group of breast cancer patients a significantly higher rate of relapse (p < 0.05) and death (p < 0.001) with tPA levels < 2.5 ng/mg. PAI-1 levels > 3 ng/mg were associated with shorter overall (p < 0.02; p = 0.01), disease-free (p < 0.008; p < 0.01), and metastasis-free (p < 0.04; p = 0.005) survival in all patients and in the node-negative subgroup, respectively. Higher uPA and cath D levels were not associated with rate of relapse or death over this follow-up period. The prognostic value of tumor-associated proteases could be of interest also in ovarian and cervical cancer.
Ruppert
C
C
Department of Gynecology and Oncology, Johann Wolfgang Goethe University Frankfurt/Main, Germany.
Ehrenforth
S
S
Scharrer
I
I
Halberstadt
E
E
D001943:Breast Neoplasms / Q000378:metabolism*; D002402:Cathepsin D / Q000378:metabolism; D018572:Disease-Free Survival; D010450:Endopeptidases / Q000378:metabolism*; D005260:Female; D005833:Genital Neoplasms, Female / Q000378:metabolism*; D006801:Humans; D009363:Neoplasm Proteins / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000378:metabolism; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D011379:Prognosis; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism
D009363:Neoplasm Proteins; D017395:Plasminogen Activator Inhibitor 1; D010450:Endopeptidases; D014568:Urokinase-Type Plasminogen Activator; D002402:Cathepsin D